Treatment and associated outcomes of type 2 diabetes mellitus patients with a cardiovascular comorbidity and comparison with guideline recommendations: a German claims data analysis
Authors' conclusion
The results from this claims database study provide important insights into real-world management of CV comorbidities in T2DM patients in Germany and underline that inconsistent guideline adherence is a major unmet challenge to healthcare providers.
Study context
- Population
- T2D-prevalent patients with an incident CV comorbidity (ischemic stroke, MI, HF or coronary artery disease) identified 2016–2018, German claims database; mean age 71.1 years
- Participants
- 17,175 patients
- Exposure
- CV guideline non-adherent vs completely adherent treatment
- Outcome
- All-cause mortality and modified 3P-MACE by guideline adherence
Methodological detailsclaims data analysis, WIG2 benchmark database
- Claims data analysis
- WIG2 benchmark database
Main finding
As reported in the abstract
Non-adherent vs Completely adherentHazard ratio (95% CI)
Mortality
1.93(1.65–2.25)
3P-MACE
1.49(1.31–1.69)
- Treated completely adherent to CV guidelines
- Around 40%
Observational data: associations, not effects.
Further findings
Survival within 12 months · 12 months follow-up
- Significantly higher survival with completely adherent vs not guideline-adherent treatment
- 90.8% vs. 82.6%
Most frequently prescribed CV treatments during follow-up
- Renin-angiotensin-aldosterone system inhibitors
- 83.9%
- Diuretics
- 72.6%
- Beta-blocking agents
- 71.8%
Original publication
Treatment and associated outcomes of type 2 diabetes mellitus patients with a cardiovascular comorbidity and comparison with guideline recommendations: a German claims data analysis. Cardiovasc Diabetol. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →